AMGN Amgen
- Official Name: AMGEN INC.
- Headquarters: One Amgen Center Drive, THOUSAND OAKS, CA, 91320-1799 US
- CEO: Robert A. Bradway
- Website: amgen.com
- Key Investor: VANGUARD GROUP INC | 9.83%
- Dedicated Investor: ROUND HILL ASSET MANAGEMENT | 9.69%
Match Results
| Date | League | Week | Opponent | Result | Score |
|---|---|---|---|---|---|
| 2025-07-17 | 1 | Lost by 2.145 | (1.528) - 0.617 | ||
| 2025-07-24 | 2 | Lost by 3.682 | 2.899 - 6.581 | ||
| 2025-07-29 | 2R | Won by 3.450 | 2.349 - (1.101) | ||
| 2025-07-31 | 3 | Lost by 12.306 | (7.955) - 4.351 | ||
| 2025-08-07 | 4 | Lost by 3.570 | (3.118) - 0.452 | ||
| 2025-08-07 | 1R | Lost by 1.554 | 0.504 - 2.058 | ||
| 2025-08-12 | 3R | Lost by 0.964 | (0.158) - 0.806 | ||
| 2025-08-14 | 5 | Won by 0.385 | 1.814 - 1.429 | ||
| 2025-08-21 | 6 | Won by 3.889 | 1.996 - (1.893) | ||
| 2025-08-28 | 7 | Lost by 1.822 | (3.537) - (1.715) | ||
| 2025-09-03 | 1R | Lost by 1.312 | (1.069) - 0.243 | ||
| 2025-09-04 | 8 | Lost by 6.693 | (1.876) - 4.817 | ||
| 2025-09-11 | 9 | Won by 2.498 | 0.937 - (1.561) | ||
| 2025-09-18 | 10 | Lost by 3.539 | (2.540) - 0.999 | ||
| 2025-09-25 | 11 | Won by 0.709 | (1.338) - (2.047) | ||
| 2025-10-02 | 12 | Won by 10.367 TOTW | 8.608 - (1.759) | ||
| 2025-10-09 | 13 | Lost by 0.546 | (0.643) - (0.097) | ||
| 2025-10-16 | 14 | Won by 2.891 | 0.130 - (2.761) | ||
| 2025-10-23 | 15 | Lost by 3.524 | (1.021) - 2.503 |
Latest News
Amgen's Q3 2026 Earnings: What to Expect
Amgen is scheduled to report its third-quarter results next month, and analysts expect a single-digit earnings rise.
What Was Eli Lilly Telling You Before Its Stock Ran?
An investor who put $10,000 into Eli Lilly (LLY) stock on October 14, 2025 held about $15,500 by October 15, 2026. Placing that same sum in the S&...
When Amgen's Forecast And Chart Say The Same Thing, Pay Attention
Amgen (AMGN) raised its revenue forecast for fiscal 2026 on August 4. Since the market close before that release, the stock has gained 15.2%, outpacin...
Is Amgen Stock Increasing Your Market Risk?
Investors holding shares of Amgen (AMGN), the $234 billion maker of drugs such as Repatha and Prolia, likely pair that position with broad exposure to...
Moderna Stock Slumps, but It’s Too Early to Panic
Moderna and Revolution Medicines have upcoming catalysts that could help sustain their gains, even as biotech stocks retreat.
9 Dow Jones Stocks Make Bullish Moves In A Defensive Market Rotation
A week that tested the financial markets showed the resilience of Dow Jones stocks. Apple and Coca-Cola were among nine standouts.
Moderna and Novavax Stocks Slump as Biotech’s Rally Takes a Breather
Moderna and Revolution Medicines have upcoming catalysts that could help sustain their gains, even as biotech stocks retreat.
Here's How Much $100 Invested In Amgen 15 Years Ago Would Be Worth Today
Amgen (NASDAQ:AMGN) has outperformed the market over the past 15 years by 1.45% on an annualized basis producing an average annual return of 14.3%. Cu...
Biogen: The Bull Case Is Extending Beyond Alzheimer's (Rating Upgrade)
Biogen's Q3 earnings are due Oct 28. Explore FY2026 EPS guidance, Alzheimerâs revenue growth, and key risk/reward driversâread now. Cli...
Amgen (AMGN) Exceeds Market Returns: Some Facts to Consider
The latest trading day saw Amgen (AMGN) settling at $434.03, representing a +1.86% change from its previous close.
Discover which dow jones stocks are making waves on Thursday.
Let's have a look at the top dow jones gainers and losers one hour before the close of the markets of today's session.
AMGN vs. MRK: Which Pharma Giant’s Dividend Actually Has Room to Grow
Amgen and Merck both yield around 2.3% and have surged this year, but one of them is paying its dividend out of thin air while the other has a cash cu...
These dow jones stocks are moving in today's session
Stay updated with the movements of the dow jones index in the middle of the day on Thursday. Discover which stocks are leading as top gainers and lose...
What Could Send Regeneron Stock Higher?
Regeneron Pharmaceuticals (REGN) may get its next boost from an old deal rather than a new drug. Through the first half of 2026, Regeneron was paying ...
Discover which dow jones stocks are making waves on Wednesday.
Uncover the latest developments among dow jones stocks in today's session. Stay tuned to the dow jones index's top gainers and losers on Wed...
Exploring the top movers within the S&P500 index during today's session.
Wondering what's happening in today's session for the S&P500 index? Stay informed with the top movers within the S&P500 index on Wed...
Amgen (AMGN) Gains Attention On Aging Treatments, Is The Upside Already Priced In?
Why Amgen Stock Is Back In Focus Amgen (AMGN) moved into the spotlight after its share price climbed sharply alongside growing attention on treatments...
What Could Amgen (AMGN) 70% Remission Trial Result Mean For Its Pipeline?
Amgen (NasdaqGS:AMGN) and AstraZeneca reported positive Phase 3 results for Tezspire in eosinophilic esophagitis on 14 October 2026. In the trial, nea...
VEEV Expands IQVIA Partnership With Clinical Operations Software Suite
Veeva expands its IQVIA partnership with clinical operations software, boosting its market reach and growth prospects through wider adoption and integ...
Can RARE's Approved Product Portfolio Drive Its Next Growth Phase?
Ultragenyx's established rare-disease treatments continue to support revenue growth, while two newly approved gene therapies offer additional com...
How to Turn $500,000 Into a Lazy $16,500 Yearly Passive Income Stream
Retirees watching CD rates scrape bottom and Treasury coupons lock in for a decade have a third option hiding in plain sight inside the Dow Jones Indu...
Bet on These Healthcare ETFs to Benefit From the Aging US Population
With the US population aging rapidly, three healthcare ETFs offer exposure to companies developing treatments, drugs and medical devices for age-relat...
Nasdaq 100 Drops 1% on Hot CPI, SOXX Falls 7th Day: Stock Market Today
The Nasdaq 100 fell 1% by midday Wednesday after September CPI topped forecasts, pushing Treasury yields and rate-hike bets higher.
Biotech Stocks To Watch: Regeneron Partner Has Breakout In Sight
Boosted by its exclusive agreement with Regeneron, Kiniksa Pharmaceuticals stands among the top biotech stocks to watch.
Blockbuster Drugs Come and Go. These 5 Pharma Dividend Stocks Keep Paying
Every big pharma company eventually watches its best-selling drug go generic, yet some keep raising their dividends anyway. The five names on this lis...
Dow Jones Industrial Average Monitor Update - A Look At 30 U.S. Large-Caps
Visible Alpha consensus expects the Dow Jones Industrial Average to deliver an 18.7% weighted price return in the medium term. Read more here.
Is Amgen Stock Worth More Than Its Competitors?
Amgen (AMGN) competes in a tight peer group of six large drugmakers alongside AbbVie, Johnson & Johnson, Merck, Pfizer, and Bristol-Myers Squibb. ...
What Is Eli Lilly Stock's Biggest Opportunity?
Investors are currently valuing Eli Lilly (LLY) stock at a premium, with shares priced at 39.5 times earnings compared with 21.9 for the S&P 500. ...
Explore the top gainers and losers within the dow jones index in today's session.
Uncover the latest developments among dow jones stocks in today's session. Stay tuned to the dow jones index's top gainers and losers on Tue...
Here’s What’s Dragging Down the Dow
A decent day for the Dow has completely flipped on its head.
Discover which dow jones stocks are making waves on Tuesday.
Curious about the dow jones stocks that are in motion on Tuesday? Join us as we explore the top movers within the dow jones index during today's ...
J&J Q3 Earnings Beat Estimates, Sales Miss, View Raised, Stock Down
JNJ beats Q3 earnings estimates but misses sales expectations as MedTech lags. It raises its 2026 sales and earnings outlook.
Guggenheim Maintains Neutral on Amgen, Lowers Price Target to $378
Guggenheim analyst Vamil Divan maintains Amgen (NASDAQ:AMGN) with a Neutral and lowers the price target from $388 to $378.
Biogen (BIIB) vs Amgen (AMGN) and Gilead (GILD): Which Big Pharma Stock is a Better Buy?
Biogen Inc. (NASDAQ:BIIB) closed at $225.71 on October 9. The stock has returned 30.5% during the last six months, compared to a 24.3% return for the ...
Uncover the latest developments among dow jones stocks in today's session.
Stay updated with the movements of the dow jones index in the middle of the day on Monday. Discover which stocks are leading as top gainers and losers...